Alpha-adrenergic agonist drugs, left ventricular function, and emergency from cardiopulmonary bypass.
The relationship between preoperative left ventricular (LV) dysfunction and the use of alpha-adrenoceptor agonists during weaning from cardiopulmonary bypass was studied in 102 patients undergoing coronary artery surgery. LV function was evaluated subjectively by examination of the 30 degree right anterior oblique left ventriculogram. Group 1 consisted of 75 patients with normal or mild impairment in LV function, whereas group 2 consisted of 27 patients with moderate-severe LV dysfunction. Cardiovascular parameters were measured at baseline, during hypothermic bypass with the aorta clamped, during normothermic bypass after unclamping, and 1 and 15 minutes after separation from bypass. Thirty-seven patients in group 1 (49%) and 11 patients in group 2 (39%) required some form of inotropic and/or vasopressor support during weaning from bypass. Group 2 required significantly higher cumulative doses of phenylephrine after bypass compared with group 1 (1.69 +/- 0.70 mg, n = 9, v 0.24 +/- 0.04 mg, n = 27, P less than 0.05). Similarly, the dose of norepinephrine infusion in group 2 was 3.3 times that in group 1 (10 +/- 6 micrograms/min, n = 2, v 3 +/- 0.6 micrograms/min, n = 2, P = NS). The higher doses of alpha-adrenoceptor agonists required in patients with moderate-severe LV dysfunction may be due to differences in alpha-adrenoceptor agonist affinity and/or receptor density.
Smith
C E
CE
Department of Cardiothoracic Anesthesia, Cleveland Clinic Foundation, OH.
Higgins
T L
TL
Kraenzler
E J
EJ
Starr
N J
NJ
Coyle
J P
JP
Licina
M G
MG
Blum
J
J
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002122:Calcium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D004280:Dobutamine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000503:physiopathology; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D009638:Norepinephrine / Q000008:administration & dosage / Q000627:therapeutic use; D010656:Phenylephrine / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology*
D000316:Adrenergic alpha-Agonists; D009599:Nitroprusside; D010656:Phenylephrine; D004280:Dobutamine; D005996:Nitroglycerin; D002122:Calcium Chloride; D009638:Norepinephrine